Journal
EXPERT REVIEW OF VACCINES
Volume 7, Issue 7, Pages 889-893Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.7.7.889
Keywords
cancer immunotherapy; modified vaccinia virus Ankara; poxvirus vaccine; therapeutic viral vaccine
Categories
Ask authors/readers for more resources
Tumor-associated antigens (TAAs) have been formulated into vaccines that, combined with adjuvants, cytokines or other strategies to boost the immune response, are now in clinical development. Both humoral and cellular immune responses to TAAs have been generated using these vaccines. This approach relies on the patient's own immune system generating an effective anti-tumor immune response. The advantage of this over therapy with monoclonal antibodies for the treatment of cancer is that multiple antigenic epitopes can be involved and the immune system is able to adapt to the most effective antigenic specificity for tumor growth control and rejection. In this article, we describe the clinical use of vaccinia virus, in particular modified vaccinia virus Ankara (MVA), to express TAAs in vivo and to stimulate an effective immune response to the cancer antigens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available